DEFA14A: Alcon-STAAR Merger Clears Key HSR Regulatory Hurdle

Alcon and STAAR Surgical announced the expiration of the Hart-Scott-Rodino waiting period, advancing Alcon's $1.5 billion acquisition of STAAR.

Summary

• The Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) waiting period for Alcon's acquisition of STAAR Surgical Company expired at 11:59 p.m. ET on September 29, 2025.
• Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash.
• The acquisition price represents approximately a 59% premium to STAAR's 90-day volume weighted average price and a 51% premium to its closing price on August 4, 2025.
• The total equity value of the transaction is approximately $1.5 billion.
• The transaction is anticipated to close within six to 12 months of the initial merger agreement announcement on August 5, 2025.
• Closing remains subject to customary conditions, including regulatory approval and approval by STAAR's stockholders.
• STAAR will hold a virtual Special Meeting of Stockholders on October 23, 2025, at 8:30 a.m. (Pacific Time) to vote on the merger proposal.
• The STAAR Board of Directors unanimously recommends that stockholders vote FOR the merger proposal.

Sentiment

Score: 8

Explanation: The filing conveys strong positive sentiment regarding the merger's progress, highlighting the successful clearance of a major regulatory hurdle and reiterating the significant premium for STAAR shareholders and strategic benefits for both companies.

Positives

• Expiration of the HSR waiting period removes a significant regulatory hurdle, indicating progress towards the merger's completion.
• STAAR stockholders are set to receive a compelling cash value of $28 per share, representing a substantial premium of approximately 59% to the 90-day VWAP and 51% to the August 4, 2025 closing price.
• The merger is expected to enable Alcon to offer treatment options across the full spectrum of myopia, reinforcing its commitment to eye care.
• Alcon's resources are anticipated to accelerate the adoption of STAAR's EVO ICL by surgeons and patients.

Risks

• The occurrence of any event, change, or circumstances that could lead to the termination of the merger agreement or delay/failure of the transaction.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain certain required regulatory approvals or to satisfy other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the transaction announcement on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others.
• Inability of STAAR to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The transaction is expected to close within six to 12 months of the initial merger agreement announcement on August 5, 2025, subject to remaining regulatory approvals and STAAR stockholder approval. Alcon anticipates offering a full spectrum of myopia treatment options, while STAAR expects to accelerate the adoption of its EVO ICL product line.

Management Comments

• David Endicott, CEO of Alcon: "We are pleased to reach this milestone towards the closing of our acquisition of STAAR. Together with STAAR, Alcon will be able to offer treatment options across the full spectrum of myopia, reinforcing our commitment to addressing the most significant needs in eye care."
• Stephen Farrell, CEO of STAAR: "With the expiration of HSR, we are one step closer toward completing this value-maximizing transaction for STAAR stockholders. In addition to providing our stockholders with compelling, certain, and premium cash value, Alcon’s resources will enable us to accelerate adoption of EVO ICL by surgeons and patients. We look forward to closing the transaction and delivering to our stakeholders its many benefits."

Industry Context

This announcement signifies a significant consolidation in the global eye care and ophthalmic surgery market. Alcon, a global leader in eye care, is acquiring STAAR Surgical, a leader in implantable phakic intraocular lenses (ICLs). This merger will broaden Alcon's product portfolio, particularly in refractive error correction, allowing it to address a wider range of myopia treatment needs and potentially increase market penetration for STAAR's EVO ICL technology.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies' financial results or project outcomes.
• The acquisition premium of approximately 59% to STAAR's 90-day VWAP and 51% to its closing price on August 4, 2025, is a key metric for evaluating the transaction's value to STAAR shareholders, often compared against typical M&A premiums in the medical device or ophthalmology sector, which can vary widely based on strategic fit, market position, and growth prospects.

Stakeholder Impact

• Shareholders of STAAR Surgical Company are expected to receive $28 per share in cash, representing a significant premium, upon the transaction's closing.
• Patients suffering from myopia are anticipated to benefit from a broader range of treatment options offered by the combined entity.
• Surgeons are expected to see accelerated adoption and availability of STAAR's EVO ICL technology due to Alcon's resources.

Next Steps

• STAAR Surgical Company will hold a virtual Special Meeting of Stockholders on October 23, 2025, to vote on the merger proposal.
• The transaction remains subject to other customary closing conditions, including additional regulatory approvals.
• The acquisition is expected to close within six to 12 months of the initial merger agreement announcement on August 5, 2025.

Key Dates

Recommendation

For STAAR shareholders, holding is recommended to receive the agreed-upon cash consideration of $28 per share upon the transaction's closing. The Hart-Scott-Rodino waiting period has expired, and the board unanimously recommends the merger, significantly de-risking the transaction. The primary remaining conditions are stockholder and final regulatory approvals, which are generally expected to proceed given this positive update.

Keywords

Alcon, STAAR Surgical, acquisition, merger, HSR, Hart-Scott-Rodino, eye care, ICL, Implantable Collamer Lens, EVO ICL, ophthalmology, medical devices, M&A